Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NYSE:QGEN NYSE:RDY NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.39$21.72▼$54.60$9.79B1.252.96 million shs2.09 million shsQGENQiagen$45.30-1.7%$48.53$37.63▼$51.88$10.07B0.641.38 million shs974,679 shsRDYDr. Reddy's Laboratories$14.65-0.5%$14.34$12.26▼$16.19$12.23B0.321.75 million shs904,411 shsXENEXenon Pharmaceuticals$36.21-2.7%$34.89$26.74▼$46.00$2.79B1.17873,579 shs562,306 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.68%+1.49%+7.15%+32.23%+87.92%QGENQiagen0.00%-2.00%-5.96%-2.16%+3.33%RDYDr. Reddy's Laboratories+0.93%+3.98%+5.86%-6.82%-7.14%XENEXenon Pharmaceuticals+0.30%-3.67%+3.42%+13.61%-3.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.39$21.72▼$54.60$9.79B1.252.96 million shs2.09 million shsQGENQiagen$45.30-1.7%$48.53$37.63▼$51.88$10.07B0.641.38 million shs974,679 shsRDYDr. Reddy's Laboratories$14.65-0.5%$14.34$12.26▼$16.19$12.23B0.321.75 million shs904,411 shsXENEXenon Pharmaceuticals$36.21-2.7%$34.89$26.74▼$46.00$2.79B1.17873,579 shs562,306 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.68%+1.49%+7.15%+32.23%+87.92%QGENQiagen0.00%-2.00%-5.96%-2.16%+3.33%RDYDr. Reddy's Laboratories+0.93%+3.98%+5.86%-6.82%-7.14%XENEXenon Pharmaceuticals+0.30%-3.67%+3.42%+13.61%-3.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9424.86% UpsideQGENQiagen 2.27Hold$49.699.68% UpsideRDYDr. Reddy's Laboratories 2.80Moderate Buy$16.9515.70% UpsideXENEXenon Pharmaceuticals 3.00Buy$53.3047.20% UpsideCurrent Analyst Ratings BreakdownLatest XENE, RDY, QGEN, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.009/3/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$48.009/2/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.008/29/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.008/15/2025RDYDr. Reddy's LaboratoriesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/12/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.008/12/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $55.008/12/2025XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $43.008/7/2025QGENQiagenCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/7/2025QGENQiagenUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$48.00 ➝ $50.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M44.12N/AN/A($7.71) per share-6.64QGENQiagen$1.98B5.09$3.16 per share14.35$16.05 per share2.82RDYDr. Reddy's Laboratories$3.81B3.21$1.04 per share14.12$4.73 per share3.10XENEXenon Pharmaceuticals$9.43M296.09N/AN/A$9.90 per share3.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)QGENQiagen$83.59M$1.6926.7618.412.4318.30%14.77%8.87%11/5/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.2017.875.8916.99%17.25%11.63%11/4/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest XENE, RDY, QGEN, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/A8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025QGENQiagen$0.60$0.60N/A$0.44$523.97 million$533.54 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AQGENQiagen$0.250.54%N/A14.79%N/ARDYDr. Reddy's Laboratories$0.070.48%N/A10.61%N/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ALatest XENE, RDY, QGEN, and BBIO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/30/2025RDYDr. Reddy's Laboratoriesannual$0.09150.623832253665189%7/25/20257/10/20258/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08QGENQiagen0.251.611.35RDYDr. Reddy's Laboratories0.011.891.36XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%QGENQiagen70.00%RDYDr. Reddy's Laboratories3.85%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%QGENQiagen9.00%RDYDr. Reddy's Laboratories2.00%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableQGENQiagen5,765222.29 million202.29 millionOptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableXENE, RDY, QGEN, and BBIO HeadlinesRecent News About These CompaniesWhy Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?September 10 at 12:30 PM | zacks.comAlliancebernstein L.P. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 9 at 4:57 AM | marketbeat.comParkman Healthcare Partners LLC Decreases Stake in Xenon Pharmaceuticals Inc. $XENESeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Purchases 78,390 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 7, 2025 | marketbeat.comWells Fargo & Company Reiterates Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)September 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Trims Position in Xenon Pharmaceuticals Inc. $XENESeptember 5, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comInvestors Buy High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)September 5, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Now Covered by Wells Fargo & CompanySeptember 5, 2025 | americanbankingnews.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at Royal Bank Of CanadaSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Has $4.28 Million Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comFirst Light Asset Management LLC Sells 532,676 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE is Vestal Point Capital LP's 9th Largest PositionSeptember 4, 2025 | marketbeat.comBirchview Capital LP Has $705,000 Stake in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Raises Stock Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 646,271 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comRoyal Bank Of Canada Reiterates Outperform Rating for Xenon Pharmaceuticals (NASDAQ:XENE)September 4, 2025 | americanbankingnews.comXenon Pharmaceuticals assumed with an Overweight at Wells FargoSeptember 3, 2025 | msn.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Braidwell LPSeptember 3, 2025 | marketbeat.comAnalysts Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Price Target at $53.20September 1, 2025 | americanbankingnews.comDriehaus Capital Management LLC Raises Stock Position in Xenon Pharmaceuticals Inc. $XENEAugust 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXENE, RDY, QGEN, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$51.21 -1.39 (-2.64%) Closing price 04:00 PM EasternExtended Trading$52.11 +0.90 (+1.76%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Qiagen NYSE:QGEN$45.30 -0.76 (-1.65%) Closing price 03:59 PM EasternExtended Trading$45.29 -0.01 (-0.02%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Dr. Reddy's Laboratories NYSE:RDY$14.65 -0.08 (-0.54%) Closing price 03:59 PM EasternExtended Trading$14.66 +0.00 (+0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Xenon Pharmaceuticals NASDAQ:XENE$36.21 -1.01 (-2.71%) Closing price 04:00 PM EasternExtended Trading$36.22 +0.01 (+0.01%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
